Skip to main content
x

OUR PASSION FOR PROGRESS™ BEGINS WITH OUR PIPELINE

For more than a decade, Neurelis has been working diligently to develop a pipeline of products and technologies to address significant unmet needs for patients.

NEURELIS PIPELINE

pipeline graphic
polygonPRE-CLIN
 
dotted circle

NRL-2

NRL-3

Phase 1PHASE
1
 
dotted circle

NRL-4*

OPNT002

Phase 2PHASE
2
 
dotted circle

 

Phase 3PHASE
3
 
dotted circle

ARS-1

OPNT003

NDANDA
 
dotted circle

 

FDAFDA
APPROVED
 
dotted circle

VALTOCO®
(diazepam nasal spray)

TOSYMRA®
(sumatriptan nasal spray)

NEURELIS PROGRAMS

NEURELIS PROGRAMS
DESCRIPTION
DISEASE STATE
STATUS
 
VALTOCO®
(diazepam nasal spray)
Diazepam Nasal Spray
Episodes of frequent seizure activity
polygonFDA Approved
 
Click here for full prescribing and important safety information.
NRL-2
Intranasal formulation with Intravail®
Acute anxiety episodes
polygonPre-Clin
NRL-3
Intranasal formulation with Intravail®
Status epilepticus
polygonPre-Clin
NRL-4
Intranasal formulation with Intravail®
Acute agitation episodes
polygonPhase 1*

Select Partner Programs

Select PARTNER PROGRAMS
DESCRIPTION
DISEASE STATE
STATUS
DETAILS
TOSYMRA®
(sumatriptan nasal spray)
Sumatriptan Nasal Spray
Acute migraine
polygonFDA Approved
  • Upsher-Smith
  • Approved - Jan 2019
 
Tosymra is a registered trademark of Upsher-Smith Laboratories, LLC. Click here for full prescribing and important safety information.
ARS-1
Epinephrine Nasal Spray
Anaphylaxis
polygonPhase 3
  • ARS Pharmaceuticals
OPNT003
Nalmefene Nasal Spray
Opioid overdose
polygonPhase 3
  • Opiant Pharmaceuticals
OPNT002
Opioid Antagonist Nasal Spray
Alcohol use disorder
polygonPhase 1
  • Opiant Pharmaceuticals

*NRL-4 completed pre-clinical phase and is expected to enter phase 1 later in 2021.

LEARN MORE ABOUT OUR INNOVATIVE PRODUCT AND PIPELINE PROGRAMS

VALTOCO
NRL-2
NRL-3
NRL-4

THE NEURELIS TEAM HAS A ROBUST HISTORY OF CNS INDUSTRY EXPERIENCE

SEE OUR TECHNOLOGIES
SEE OUR PARTNERS